{"id":"09e2bdbd963b","type":"article","url":"https://hartvaat.nl/2026/03/03/evolocumab-naast-empagliflozine-verandert-ldl-subdeeltjes-bij-type-2-diabetes/","title":"Evolocumab naast empagliflozine verandert LDL-subdeeltjes bij type 2 diabetes","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["bempedoïnezuur","diabetes-en-hart","diabetes-type-2","empagliflozine","emperor-trials","ezetimibe","figaro-dkd","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","soul-trial","statines"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00052-3/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00052-3/fulltext","authors":["Isabella Bonilha","Marcos Yukio Yoshinaga","Adriano Britto Chaves-Filho","Érica Ivana Lázaro Gomes","Rosangela Silva Santos","Ikaro Breder","Jessica Breder","Sayuri Miyamoto","Wilson Nadruz","Anatol Kontush","Andrei C. Sposito"],"significance":5,"published":"2026-04-08","source_date":"2026-03-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/preventie/preventie-bij-diabetes/"],"congress":"","summary_en":"In a pre-specified analysis of a randomised trial, the addition of the PCSK9 inhibitor evolocumab to empagliflozin in type 2 diabetes was found to alter LDL subparticle composition and the lipidome beyond standard LDL-cholesterol reduction, potentially contributing to the cardiovascular benefits of this combination therapy.","created":"2026-07-03T10:32:43Z","updated":"2026-07-03T13:31:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een vooraf gespecificeerde analyse van een gerandomiseerde trial werd onderzocht of toevoeging van de PCSK9-remmer evolocumab aan empagliflozine bij type 2 diabetes het LDL-fenotype en lipidoom verandert. Naast de bekende LDL-cholesterolverlaging werden verschuivingen in LDL-subdeeltjes gevonden, wat kan bijdragen aan het begrip van de cardiovasculaire voordelen van deze combinatietherapie.","abstract_original":"Sodium–glucose cotransporter-2 inhibitors (SGLT2i) and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) reduce cardiovascular risk in type 2 diabetes. Whether these benefits are partly mediated by modifications in low-density lipoprotein (LDL) phenotype, beyond changes in LDL-cholesterol levels, remains unknown."}